Cure Today15h
The Subcutaneous Approval of Opdivo Makes Waves in Future of Cancer Care
Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...
BioWorld14h
OS Therapies heading to FDA with positive osteosarcoma data
With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies ...
Clinical trial: Off-the-shelf immunotherapy shows promise for B-cell lymphoma
A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...
FDA approves subcutaneous opdivo qvantig for most solid tumor indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
Renal & Urology News9d
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
Armed robbery in Revesby1d
New Cellular Immunotherapy Promising for B-cell Lymphoma
A new type of cell-based immunotherapy shows promise for B-cell lymphomas and — due to innovations in manufacturing — could make future cellular ...
EurekAlert!2d
New cellular immunotherapy approach shows promise for B-cell lymphoma
A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...
Cure Today4d
A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval
Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.
Two clinical trials show that immunotherapy with current treatment is effective.
Immunotherapy, a form of treatment that uses the body’s immune system to find and fight cancer cells, can delay the ...
Targeted Oncology13d
FDA Signals Potential for Standard Approval of Paxalisib in Glioblastoma
The FDA indicated paxalisib's overall survival data could support standard approval in glioblastoma, as supported by ...